Last Posted: Nov 03, 2019
- Year in Review: Ovarian Cancer: PARP inhibitors, genetic testing, and novel combinations
I Ingram, Medpage Today, November 1, 2019 - The BRCA gene is about so much more than breast cancer risk
A Goldman, Well and Good, October 27, 2019 - Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer.
Abulkhair Omalkhair et al. Journal of global oncology 2018 41-9 - The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.
Kubelac Paul et al. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 24(4) 1538-1543 - Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?
Kotsopoulos Joanne et al. Menopause (New York, N.Y.) 2019 Oct - Calling on Primary Care to Prevent BRCA-Related Cancers.
Armstrong Katrina et al. Journal of general internal medicine 2019 Oct - From Genetic Testing to Treatment and Prevention of BRCA-Related Breast Cancer.
Ki Chang Seok et al. Annals of laboratory medicine 2020 Mar 40(2) 99-100 - 25 Years of BRCA: How a Cancer Milestone Has Changed the Field
J Infanti, Penn Medicine Blog, October 2019 - Angelina Jolie: Medical Advances in Women's Health Are Important. But They're Only Part of the Picture
A Jolie, Time, October 24, 2019 - Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
Veneris Jennifer Taylor et al. Gynecologic oncology 2019 Oct
No hay comentarios:
Publicar un comentario